IDEAYA reports cash $373.1M, net loss $58.7M; darovasertib data mid-2023

IDEAYA Biosciences, Inc.

Cash, cash equivalents and marketable securities $373.1M as of Dec 31, 2022; sufficient to fund operations into 2026.
Net loss $58.7M for FY2022 vs $49.8M in FY2021; Q4 collaboration revenue $4.0M vs $3.0M.
Targeting mid-2023 clinical efficacy update for darovasertib/crizotinib in ~20 first-line MUM patients; goals: >20% ORR, >5 months mPFS.
First-patient dosing of IDE161 (PARG) in Q1 2023; IND submission for Pol Theta Helicase in Q2 2023 with GSK.
Discontinuing IDE397+chemo cohorts; prioritizing IDE397/AMG193 combination with Amgen.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IDEAYA Biosciences, Inc. reported financial results for year ended December 31, 2022.

Period: year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 7, 2023, IDEAYA Biosciences, Inc. (the “Company”) announced its financial results for the fourth quarter and full year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

IDEAYA Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-006349

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.